Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3112260 | 0.84 | FAAH (0.33) | CA2FAAH | |
| SCHEMBL3112274 | 0.83 | CA2 (0.41) | CA2TP53SMN1; SMN2NPC1S1PR2 | |
| SCHEMBL3105085 | 0.77 | CA2 (0.48) | CA2TP53SMN1; SMN2NPC1S1PR2 | |
| SCHEMBL3117557 | 0.75 | — | — | |
| SCHEMBL2306255 | 0.75 | CA2 (0.47) | CA2TP53SMN1; SMN2NPC1S1PR2 | |
| SCHEMBL2305626 | 0.74 | CA2 (0.50) | CA2TP53SMN1; SMN2NPC1S1PR2 | |
| SCHEMBL8778761 | 0.73 | CA2 (0.41) | CA2TP53SMN1; SMN2NPC1S1PR2 | |
| SCHEMBL6227507 | 0.72 | CA2 (0.52) | CA2TP53SMN1; SMN2NPC1S1PR2 | |
| SCHEMBL751665 | 0.72 | CA2 (0.43) | CA2TP53SMN1; SMN2NPC1S1PR2 | |
| SCHEMBL27845303 | 0.71 | CA2 (0.39) | CA2TP53SMN1; SMN2NPC1S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | KANG, XINSHAN (CN) | 2016-07-14 | — | — | US | disclosed |
| US-8222417-B2 | Compound having 11β-HSD1 inhibitory activity | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20100179325-A1 | COMPOUND HAVING 11BETA-HSD1 INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2172453-A1 | COMPOUND HAVING 11 ß-HSD1 INHIBITORY ACTIVITY | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179325-A1 | COMPOUND HAVING 11BETA-HSD1 INHIBITORY ACTIVITY | HSD11B1, CYP4A11, HSD11B2 | CA2 571/4885TP53 4755/4885SMN1; SMN2 3948/4885 |
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | GPR119, GLP1R, INSR | CA2 693/4885TP53 1753/4885SMN1; SMN2 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.